Eosinophil cationic protein alters pulmonary surfactant structure and function in asthma

Journal of Allergy and Clinical Immunology

Volumn 113, Issue 3, 2004, Pages 496-502

  Hohlfeld, Jens M ^a,b   Schmiedl, Andreas ^a   Erpenbeck, Veit J ^a,b   Venge, Per ^c   Krug, Norbert ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Airway obstruction; Asthma; Eosinophils; Surfactant function; Surfactant ultrastructure

Indexed keywords

ALBUMIN; EOSINOPHIL CATIONIC PROTEIN; FIBRINOGEN; LUNG SURFACTANT;

ADULT; AIRWAY OBSTRUCTION; ALLERGIC ASTHMA; ALLERGY TEST; ARTICLE; CELL ULTRASTRUCTURE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FEMALE; HUMAN; INCUBATION TIME; INTERMETHOD COMPARISON; LUNG LAVAGE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; PROVOCATION TEST;

EID: 1542407026     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2003.12.008     Document Type: Article

References (28)

1. Enhorning G. Pulmonary surfactant function in alveoli and conducting airways. Can Respir J 1996;3:21-7.
2. Hohlfeld J, Fabel H, Hamm H. The role of pulmonary surfactant in obstructive airways disease. Eur Respir J 1997;10:482-91.
3. Hohlfeld JM, Ahlf K, Enhorning G, Balke K, Erpenbeck VJ, Petschallies J, et al. Dysfunction of pulmonary surfactant in asthmatics after segmental allergen challenge. Am J Respir Crit Care Med 1999;159:1803-9.
4. Jarjour NN, Enhorning G. Antigen-induced airway inflammation in atopic subjects generates dysfunction of pulmonary surfactant. Am J Respir Crit Care Med 1999;160:336-41.
5. Kurashima K, Fujimura M, Matsuda T, Kobayashi T. Surface activity of sputum from acute asthmatic patients. Am J Respir Crit Care Med 1997;155:1254-9.
6. Seeger W, Grube C, Günther A, Schmidt R. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J 1993;6:971-7.
7. Heeley EL, Hohlfeld JM, Krug N, Postle AD. Phospholipid molecular species of bronchoalveolar lavage fluid after local allergen challenge in asthma. Am J Physiol (Lung Cell Mol Physiol) 2000;278:L305-11.
8. Venge P. The human eosinophil in inflammation. Agents Action 1990;29:122-6.
9. Lacoste JY, Bousquet J, Chanez P, Van Vyve T, Simony-Lafontaine J. Lequeu N, et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993;92:537-48.
10. Fujimoto K, Kubo K, Matsuzawa Y, Sekiguchi M. Eosinophil cationic protein levels in induced sputum correlate with the severity of bronchial asthma. Chest 1997;112:1241-7.
11. National Heart, Lung, and Blood Institute. International consensus report on diagnosis and treatment of asthma. Eur Respir J 1992;5:601-41.
12. Cockcroft DW, Killian DN, Mellon JJ, Hargreave FE. Bronchoreactivity to inhaled histamine: a method and clinical survey. Clin Allergy 1977;7:235-43.
13. Krug N, Erpenbeck VJ, Balke K, Petschallies J, Tschernig T, Hohlfeld JM, et al. Cytokine profile of bronchoalveolar lavage-derived CD4+, CD8+, and γd T cells in people with asthma after segmental allergen challenge. Am J Respir Cell Mol Biol 2001;25:125-31.
14. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75.
15. Liu M, Wang L, Li E, Enhorning G. Pulmonary surfactant will secure free airflow through a narrow tube. J Appl Physiol 1991;71:742-8.
16. Enhorning G, Holm BA. Disruption of pulmonary surfactant's ability to maintain openness of a narrow tube. J Appl Physiol 1993;74:2922-7.
17. Weibel ER. A simplified morphometric method for estimating diffusing capacity in normal and emphysematous human lungs. Am Rev Respir Dis 1973;107:579-88.
18. Rosner BA. Fundamentals in Biostatistics. 4th ed. Belmont (CA): Duxberry Press; 1995.
19. Enhorning G, Duffy LC, Welliver RC. Pulmonary surfactant maintains patency of conducting airways in the rat. Am J Respir Crit Care Med 1995;151:554-6.
20. Hohlfeld JM. The role of pulmonary surfactant in asthma. Respir Res 2002;3:4.
21. Woolley KL, Adelroth E, Woolley MJ, Ellis R, Jordana M, O'Byrne PM. Effects of allergen challenge on eosinophils, eosinophil cationic protein, and granulocyte-macrophage colony-stimulating factor in mild asthma. Am J Respir Crit Care Med 1995;151:1915-24.
22. Shaver JR, Zangrilli JG, Cho SK, Cirelli RA, Pollice M, Hastie AT, et al. Kinetics of the development and recovery of the lung from IgE-mediated inflammation: dissociation of pulmonary eosinophilia, lung injury, and eosinophil-active cytokines. Am J Respir Crit Care Med 1997;155:442-8.
23. Peebles RSJ, Liu MC, Adkinson NFJ, Lichtenstein LM, Hamilton RG. Ragweed-specific antibodies in bronchoalveolar lavage fluids and serum before and after segmental lung challenge: IgE and IgA associated with eosinophil degranulation. J Allergy Clin Immunol 1998;101:265-73.
24. Seeger W, Stohr G, Wolf HRD, Neuhof H. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol 1985;58:326-38.
25. Schmekel B, Venge P. The distribution of myeloperoxidase, eosinophil cationic protein, albumin and urea in sequential bronchoalveolar lavage. Eur Respir J 1991;4:517-23.
26. Fahy JV, Wong H, Liu J, Boushey HA. Comparison of samples collected by sputum induction and bronchoscopy from asthmatic and healthy subjects. Am J Respir Crit Care Med 1995;152:53-8.
27. Young JDE, Peterson CGB, Venge P, Cohn ZA. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature 1986;321:613-6.
28. Lee LY, Gu Q, Gleich GJ. Effects of human eosinophil granule-derived cationic protein on C-fiber afferents in the rat lung. J Appl Physiol 2001;91:1318-26.